Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-ps12-09
H. McArthur, S. Shiao, S. Karlan, R. Basho, F. Amersi, B. Arnold, M. Burnison, A. Chung, C. Chung, C. Dang, A. Giuliano, Nimmi S. Kapoor, Negin Habibi Khameneh, S. Knott, Cynthia Martin, P. McAndrew, M. Mita, D. Park, C. Abaya, A. Ho
{"title":"Abstract PS12-09: Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC)","authors":"H. McArthur, S. Shiao, S. Karlan, R. Basho, F. Amersi, B. Arnold, M. Burnison, A. Chung, C. Chung, C. Dang, A. Giuliano, Nimmi S. Kapoor, Negin Habibi Khameneh, S. Knott, Cynthia Martin, P. McAndrew, M. Mita, D. Park, C. Abaya, A. Ho","doi":"10.1158/1538-7445.sabcs20-ps12-09","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-ps12-09","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74960022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS1-12
S. Rama, Cara Canella, Jenna Luker, Kelley Park, R. Barry, Saheli Ghosh, Simeng Zhu, Yalei Chen, J. Bensenhaver, E. Walker, K. Levin, D. Atisha, M. Evangelista
Purpose/Objective(s):Unlike temporary breast edema caused by post-lumpectomy radiation therapy (RT), the edema that persists beyond one year is not well defined and difficult to treat. The aim of this study is to define the incidence and risk factors for the development of chronic breast lymphedema in women undergoing lumpectomy with RT at a large metropolitan cancer center. Materials/Methods:A retrospective chart review was performed on all patients who underwent lumpectomy from 2014 to 2018. Women who did not undergo RT at our institution and those with stage IV disease were excluded from the analysis. Patient demographics, comorbidities, operative data, RT data and postoperative complications were obtained. Chronic breast lymphedema (CBL) was defined as edema that persisted beyond one year post completion of radiation therapy. Breast volumes were determined by contoured breast volumes or, if unavailable, estimated by the 95% isodose volumes from the RT treatment planning system. Using a density curve, the distribution of breast volumes was plotted for patients with and patients without CBL. Univariate analysis was used to evaluate factors associated with CBL. Multivariate regression analysis was used to evaluate factors associated with the risk of CBL while accounting for potential confounding variables as defined by the univariate analysis. Results:A total of 1173 patients were included for analysis. Seventy-four (6.3%) patients developed breast lymphedema beyond one year. For the entire cohort, mean age was 63 years old (SD=11.17), mean BMI was 31.15 kg/m2 (SD=7.17), mean breast volume was 1198.54 cm3 (SD=645.82 cm3), mean total radiation was 59.18 Gy (SD=16.76), and 139 (11.8%) patients underwent ALND. Compared to the cohort that did not develop CBL (n=1099), the CBL cohort (n=74) had a higher median BMI (33.23 kg/m2 vs. 29.81 kg/m2, P Conclusion:Chronic breast lymphedema presents a clinical concern for women undergoing lumpectomy with postoperative radiation, particularly in women with larger breasts. Further studies should focus on preventative strategies, as well as the psychosocial and economic impact of this morbidity. Citation Format: Sanjay Rama, Cara Canella, Jenna Luker, Kelley Park, Renee Barry, Saheli Ghosh, Simeng Zhu, Yalei Chen, Jessica Bensenhaver, Eleanor Walker, Kenneth Levin, Dunya Atisha, Maristella Evangelista. Factors associated with chronic breast lymphedema after adjuvant radiation in women undergoing breast conservation therapy [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS1-12.
{"title":"Abstract PS1-12: Factors associated with chronic breast lymphedema after adjuvant radiation in women undergoing breast conservation therapy","authors":"S. Rama, Cara Canella, Jenna Luker, Kelley Park, R. Barry, Saheli Ghosh, Simeng Zhu, Yalei Chen, J. Bensenhaver, E. Walker, K. Levin, D. Atisha, M. Evangelista","doi":"10.1158/1538-7445.SABCS20-PS1-12","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS1-12","url":null,"abstract":"Purpose/Objective(s):Unlike temporary breast edema caused by post-lumpectomy radiation therapy (RT), the edema that persists beyond one year is not well defined and difficult to treat. The aim of this study is to define the incidence and risk factors for the development of chronic breast lymphedema in women undergoing lumpectomy with RT at a large metropolitan cancer center. Materials/Methods:A retrospective chart review was performed on all patients who underwent lumpectomy from 2014 to 2018. Women who did not undergo RT at our institution and those with stage IV disease were excluded from the analysis. Patient demographics, comorbidities, operative data, RT data and postoperative complications were obtained. Chronic breast lymphedema (CBL) was defined as edema that persisted beyond one year post completion of radiation therapy. Breast volumes were determined by contoured breast volumes or, if unavailable, estimated by the 95% isodose volumes from the RT treatment planning system. Using a density curve, the distribution of breast volumes was plotted for patients with and patients without CBL. Univariate analysis was used to evaluate factors associated with CBL. Multivariate regression analysis was used to evaluate factors associated with the risk of CBL while accounting for potential confounding variables as defined by the univariate analysis. Results:A total of 1173 patients were included for analysis. Seventy-four (6.3%) patients developed breast lymphedema beyond one year. For the entire cohort, mean age was 63 years old (SD=11.17), mean BMI was 31.15 kg/m2 (SD=7.17), mean breast volume was 1198.54 cm3 (SD=645.82 cm3), mean total radiation was 59.18 Gy (SD=16.76), and 139 (11.8%) patients underwent ALND. Compared to the cohort that did not develop CBL (n=1099), the CBL cohort (n=74) had a higher median BMI (33.23 kg/m2 vs. 29.81 kg/m2, P Conclusion:Chronic breast lymphedema presents a clinical concern for women undergoing lumpectomy with postoperative radiation, particularly in women with larger breasts. Further studies should focus on preventative strategies, as well as the psychosocial and economic impact of this morbidity. Citation Format: Sanjay Rama, Cara Canella, Jenna Luker, Kelley Park, Renee Barry, Saheli Ghosh, Simeng Zhu, Yalei Chen, Jessica Bensenhaver, Eleanor Walker, Kenneth Levin, Dunya Atisha, Maristella Evangelista. Factors associated with chronic breast lymphedema after adjuvant radiation in women undergoing breast conservation therapy [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS1-12.","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85123382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-ps10-10
H. A. Razeq, P. Cottu, A. Ring, M. de Laurentiis, Janice M. Lu, H. Azim, C. Zamagni, K. Zhou, Jiwen Wu, L. Menon-Singh, Miguel Martín
{"title":"Abstract PS10-10: Ribociclib + letrozole in premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial","authors":"H. A. Razeq, P. Cottu, A. Ring, M. de Laurentiis, Janice M. Lu, H. Azim, C. Zamagni, K. Zhou, Jiwen Wu, L. Menon-Singh, Miguel Martín","doi":"10.1158/1538-7445.sabcs20-ps10-10","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-ps10-10","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88385273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS1-21
H. Kolberg, C. Röhm, A. Stachs, F. Schütz, J. Blohmer, S. Wetzig, S. Hartmann, J. Heil, M. Hahn
Introduction: The goal of breast conserving surgery (BCS) for early breast cancer (EBC) is to remove the tumor in toto and preserving as much of the normal breast tissue as possible. In 20-50% of cases a re-excision is necessary because of involved margins. Repeat surgeries are not only a burden to patients physically but also psychologically and can delay recommended adjuvant therapies. Accurate determination of tumor margins during surgery is therefore a critical need. Breast cancer tissue produces significantly higher amounts of VEGF-A than healthy tissue. VEGF-A stimulates tumor angiogenesis and is therefore a target for molecular imaging techniques. The fluorescence imaging agent bevacizumab-IRDye800CW (Beva800) is a conjugate of bevacizumab and IRDye800CW and binds specifically to VEGF-A. Beva800 provides a potentially efficacious approach to imaging specimen and cavity margins during BCS. We are presenting a phase II study that combined Beva800 with the SurgVision Explorer Air camera for intraoperative margin assessment during BCS for EBC. Methods: MARGIN II is a multicenter open-label single arm prospective clinical trial aimed at evaluating Beva800 for assessment of tumor margins in women with EBC scheduled for BCS. The study was a within-patient comparison of positive tumor margin rates using BCS standard of care margin assessment compared to intraoperative assessment with 4.5 mg Beva800 and fluorescence imaging with the SurgVision Explorer Air camera. All patients received an i.-v. bolus injection of 4.5 mg of Beva800 three days before surgery. The fluorescent signal was visualized during surgery using NIR fluorescence imaging (700–1000 nm). Standard of care margin assessment was defined as visual inspection, palpation and, in cases of pre-operative wire marking, specimen sonography or mammography. Beva800 efficacy was determined as the number of patients in which a pathology-confirmed positive margin was identified by fluorescence-guided surgery using Beva800 but not by standard of care BCS. Results: 49 patients were included in 5 centers. 4 training cases were only included in the safety analysis, 45 patients were evaluable for the efficacy analysis. 8 patients (17.8%) had involved margins after standard of care BCS, 4 of which were detected by molecular fluorescence intraoperatively resulting in the reduction of patients with positive margins by 50% (95% CI: 15.7%, 84.3%). 4 patients (8.9%; 95% CI: 2.5%, 21.1%) needed a re-excision because of involved margins. In 27 patients (60.0%) the additional molecular fluorescence guided cavity shaving did not change the resection status from positive to negative (false positive). Adverse events were reported by 16 of 49 patients (32.7%), but only 3 (6.1%) were related to Beva800 (syncope, hot flush, hypertensive crisis). One patient experienced a treatment related SAE (hypertensive crisis). No anti-Beva800 antibodies were detected. Conclusion: In our analysis the rate of necessary second op
早期乳腺癌(EBC)保乳手术(BCS)的目标是全部切除肿瘤并尽可能多地保留正常乳腺组织。在20-50%的病例中，由于边缘受累，需要再次切除。重复手术不仅是患者身体上的负担，也是心理上的负担，并可能延迟推荐的辅助治疗。因此，在手术中准确确定肿瘤边缘是非常必要的。乳腺癌组织产生的VEGF-A明显高于健康组织。VEGF-A刺激肿瘤血管生成，因此是分子成像技术的靶标。荧光显像剂贝伐单抗-IRDye800CW (Beva800)是贝伐单抗和IRDye800CW的缀合物，特异性结合VEGF-A。Beva800提供了一种潜在的有效方法来成像BCS期间的标本和腔缘。我们正在进行一项II期研究，该研究将Beva800与SurgVision Explorer Air相机相结合，用于EBC BCS术中边缘评估。方法:MARGIN II是一项多中心开放标签单臂前瞻性临床试验，旨在评估Beva800对计划接受BCS的EBC女性肿瘤边缘的评估作用。该研究是一项患者内肿瘤边缘阳性率的比较，采用BCS标准护理边缘评估，与术中使用4.5 mg Beva800评估和使用SurgVision Explorer Air相机进行荧光成像进行比较。所有病人都接受了静脉注射。在手术前三天注射4.5毫克的Beva800。术中荧光信号采用近红外荧光成像(700-1000 nm)。护理标准边缘评估定义为目视检查，触诊，以及术前线标记的情况下，标本超声检查或乳房x光检查。Beva800的疗效是指使用Beva800进行荧光引导手术，但未使用标准护理BCS，病理证实的阳性边缘的患者数量。结果:49例患者被纳入5个中心。4例训练病例仅纳入安全性分析，45例患者可评价疗效分析。8例患者(17.8%)在标准护理BCS后出现边缘病变，其中4例术中通过分子荧光检测，导致边缘阳性患者减少50% (95% CI: 15.7%， 84.3%)。4例(8.9%);95% CI: 2.5%， 21.1%)因累及切缘需要再次切除。在27例(60.0%)患者中，额外的分子荧光引导空腔刮除未使切除状态从阳性变为阴性(假阳性)。49例患者中有16例(32.7%)报告了不良事件，但只有3例(6.1%)与Beva800有关(晕厥、潮热、高血压危象)。1例患者出现与治疗相关的SAE(高血压危象)。未检出抗beva800抗体。结论:在我们的分析中，使用Beva800和SurgVision Explorer Air相机，必要的第二次手术率降低了50%。安全性分析证实了先前研究中发现的Beva800的积极安全性。分子荧光引导手术有可能通过减少不必要的再切除来改变保乳手术的实践。未来的研究将不得不解决高假阳性率。引文格式:Hans-Christian Kolberg, Carmen Röhm, Angrit Stachs, Florian sch z, Jens-Uwe Blohmer, Sarah Wetzig, Steffi Hartmann, Jörg Heil, Markus Hahn。分子荧光引导下的BEVA800在原发乳腺癌保乳手术中评估肿瘤边缘(MARGIN-II)[摘要]。摘自:2022年圣安东尼奥乳腺癌研讨会论文集;2022年12月6日至10日;费城(PA): AACR;癌症杂志，2013;31(5增刊):02 - 02。
{"title":"Abstract PS1-21: Molecular fluorescence-guided surgery using Beva800 for the assessment of tumor margins during breast conserving surgery of patients with primary breast cancer (MARGIN-II)","authors":"H. Kolberg, C. Röhm, A. Stachs, F. Schütz, J. Blohmer, S. Wetzig, S. Hartmann, J. Heil, M. Hahn","doi":"10.1158/1538-7445.SABCS20-PS1-21","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS1-21","url":null,"abstract":"\u0000 Introduction: The goal of breast conserving surgery (BCS) for early breast cancer (EBC) is to remove the tumor in toto and preserving as much of the normal breast tissue as possible. In 20-50% of cases a re-excision is necessary because of involved margins. Repeat surgeries are not only a burden to patients physically but also psychologically and can delay recommended adjuvant therapies. Accurate determination of tumor margins during surgery is therefore a critical need. Breast cancer tissue produces significantly higher amounts of VEGF-A than healthy tissue. VEGF-A stimulates tumor angiogenesis and is therefore a target for molecular imaging techniques. The fluorescence imaging agent bevacizumab-IRDye800CW (Beva800) is a conjugate of bevacizumab and IRDye800CW and binds specifically to VEGF-A. Beva800 provides a potentially efficacious approach to imaging specimen and cavity margins during BCS. We are presenting a phase II study that combined Beva800 with the SurgVision Explorer Air camera for intraoperative margin assessment during BCS for EBC. Methods: MARGIN II is a multicenter open-label single arm prospective clinical trial aimed at evaluating Beva800 for assessment of tumor margins in women with EBC scheduled for BCS. The study was a within-patient comparison of positive tumor margin rates using BCS standard of care margin assessment compared to intraoperative assessment with 4.5 mg Beva800 and fluorescence imaging with the SurgVision Explorer Air camera. All patients received an i.-v. bolus injection of 4.5 mg of Beva800 three days before surgery. The fluorescent signal was visualized during surgery using NIR fluorescence imaging (700–1000 nm). Standard of care margin assessment was defined as visual inspection, palpation and, in cases of pre-operative wire marking, specimen sonography or mammography. Beva800 efficacy was determined as the number of patients in which a pathology-confirmed positive margin was identified by fluorescence-guided surgery using Beva800 but not by standard of care BCS. Results: 49 patients were included in 5 centers. 4 training cases were only included in the safety analysis, 45 patients were evaluable for the efficacy analysis. 8 patients (17.8%) had involved margins after standard of care BCS, 4 of which were detected by molecular fluorescence intraoperatively resulting in the reduction of patients with positive margins by 50% (95% CI: 15.7%, 84.3%). 4 patients (8.9%; 95% CI: 2.5%, 21.1%) needed a re-excision because of involved margins. In 27 patients (60.0%) the additional molecular fluorescence guided cavity shaving did not change the resection status from positive to negative (false positive). Adverse events were reported by 16 of 49 patients (32.7%), but only 3 (6.1%) were related to Beva800 (syncope, hot flush, hypertensive crisis). One patient experienced a treatment related SAE (hypertensive crisis). No anti-Beva800 antibodies were detected. Conclusion: In our analysis the rate of necessary second op","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"121 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76804210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-ps6-01
L. J. van ’t Veer, Fatima Cardoso, C. Poncet, J.Lopes Cardozo, S. Delaloge, J. Pierga, P. Vuylsteke, E. Brain, G. Viale, S. Kümmel, I. Rubio, G. Zoppoli, Alistair Thompson, E. Matos, K. Zaman, S. Knox, F. Hilbers, A. Peric, B. Meulemans, Martine Picccart, E. J. Th. Rutgers
{"title":"Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status","authors":"L. J. van ’t Veer, Fatima Cardoso, C. Poncet, J.Lopes Cardozo, S. Delaloge, J. Pierga, P. Vuylsteke, E. Brain, G. Viale, S. Kümmel, I. Rubio, G. Zoppoli, Alistair Thompson, E. Matos, K. Zaman, S. Knox, F. Hilbers, A. Peric, B. Meulemans, Martine Picccart, E. J. Th. Rutgers","doi":"10.1158/1538-7445.sabcs20-ps6-01","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-ps6-01","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73194072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS6-25
L. Vian, R. P. Souza, V. C. C. Lima, Daniella Yumi Tsuji Honda, S. T. Pacheco, Caio Dabbous de Liz, L. Gomes, Bruno Cezar Mendonça Uchôa Júnior, P. Guimarães, Celso Silva e Souza Filho, A. Guimarães, M. F. Simões, M. Donadio, Â. Fêde, A. Saito, A. Ribeiro, Joyce Maria L. Maia, I.K.F. Lustosa, F. Sanchez Castro, M. C. Tavares, M. Cesca, M. Corassa, N. Pondé, S. Sanches
{"title":"Abstract PS6-25: Cts5 tested in a Brazilian population: A tool that can predict global survival in early breast cancer ER+/HER2-, as well as the response to extended endocrine therapy","authors":"L. Vian, R. P. Souza, V. C. C. Lima, Daniella Yumi Tsuji Honda, S. T. Pacheco, Caio Dabbous de Liz, L. Gomes, Bruno Cezar Mendonça Uchôa Júnior, P. Guimarães, Celso Silva e Souza Filho, A. Guimarães, M. F. Simões, M. Donadio, Â. Fêde, A. Saito, A. Ribeiro, Joyce Maria L. Maia, I.K.F. Lustosa, F. Sanchez Castro, M. C. Tavares, M. Cesca, M. Corassa, N. Pondé, S. Sanches","doi":"10.1158/1538-7445.SABCS20-PS6-25","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS6-25","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74449309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-ps14-03
M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Pálácova, S. Chatterjee, L. Menon-Singh, Jiwen Wu, K. Zhou, Miguel Martín
{"title":"Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial","authors":"M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Pálácova, S. Chatterjee, L. Menon-Singh, Jiwen Wu, K. Zhou, Miguel Martín","doi":"10.1158/1538-7445.sabcs20-ps14-03","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-ps14-03","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76099254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS2-31
I. Garrido-Cano, V. Constâncio, A. Adam-Artigues, A. Lameirinhas, S. Simón, B. Ortega, M. T. Martínez, C. Hernando, B. Bermejo, A. Lluch, P. Lopes, R. Henrique, C. Jerónimo, J. Cejalvo, P. Eroles
{"title":"Abstract PS2-31: Circulating miR-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer","authors":"I. Garrido-Cano, V. Constâncio, A. Adam-Artigues, A. Lameirinhas, S. Simón, B. Ortega, M. T. Martínez, C. Hernando, B. Bermejo, A. Lluch, P. Lopes, R. Henrique, C. Jerónimo, J. Cejalvo, P. Eroles","doi":"10.1158/1538-7445.SABCS20-PS2-31","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS2-31","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78362214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS18-38
Lori A. Sturtz, Guisong Wang, Punit Shah, R. Searfoss, Praveen-Kumar Raj-Kumar, J. Hooke, J. Fantacone-Campbell, B. Deyarmin, M. Cutler, R. Sarangarajan, N. Narain, Hai Hu, M. Kiebish, A. Kovatich, C. Shriver
Background: Proteomic studies are typically conducted using flash-frozen (FF) samples utilizing tandem mass spectrometry. However, FF samples are comprised of multiple cell types, making it difficult to ascertain the proteomic profiles of specific cells. Conversely, OCT-embedded (Optimal Cutting Temperature compound) specimens can undergo laser microdissection (LMD) to capture and study specific cell types separately from the cell mixture. In the current study, we compared proteomic data obtained from FF and OCT samples to determine if samples that are stored and processed differently produce comparable results. Methods: Proteins were extracted from FF and OCT-embedded invasive breast tumors from 5 female patients. FF samples were lysed via homogenization (FF/HOM) while OCT-embedded specimens underwent LMD to collect only tumor cells (OCT/LMD-T) or both tumor and stromal cells (OCT/LMD-TS) followed by incubation at 37°C. Proteins were extracted using the illustra triplePrep kit and then trypsin-digested, TMT-labeled, and processed by two-dimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS). Proteins were identified and quantified with Proteome Discoverer v1.4 and comparative analyses performed to identify proteins that were significantly differentially expressed amongst the different processing methods. Results: Among 4,950 proteins consistently quantified across all samples, 216 and 171 proteins were significantly differentially expressed (adjusted p-value 1) between FF/HOM vs. OCT/LMD-T and FF/HOM vs. OCT/LMD-TS, respectively, with most proteins being more highly abundant in the FF/HOM samples. PCA and unsupervised hierarchical clustering analysis with these 216 and 171 proteins were able to distinguish FF/HOM from OCT/LMD-T and OCT/LMD-TS samples, respectively. Likewise, PCA analysis and unsupervised clustering analysis using the 402 and 60 significantly differentially enriched GO terms (adjusted p-value (BH) Citation Format: Lori A. Sturtz, Guisong Wang, Punit Shah, Richard Searfoss, Praveen-Kumar Raj-Kumar, Jeffrey A. Hooke, J. Leigh Fantacone-Campbell, Brenda Deyarmin, Mary Lou Cutler, Rangaprasad Sarangarajan, Niven R. Narain, Hai Hu, Michael A. Kiebish, Albert J. Kovatich, Craig D. Shriver. Comparative analysis of differentially abundant proteins quantified by LC-MS/MS between flash frozen and laser microdissected OCT-embedded breast tumor samples [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS18-38.
背景:蛋白质组学研究通常使用快速冷冻(FF)样品进行串联质谱分析。然而，FF样品由多种细胞类型组成，因此很难确定特定细胞的蛋白质组学特征。相反，oct包埋(最佳切割温度化合物)标本可以进行激光显微解剖(LMD)，以从细胞混合物中单独捕获和研究特定的细胞类型。在目前的研究中，我们比较了从FF和OCT样品中获得的蛋白质组学数据，以确定存储和处理方式不同的样品是否产生可比较的结果。方法:分别从5例女性乳腺浸润性肿瘤FF和oct中提取蛋白。FF样品通过均质化(FF/HOM)裂解，OCT包埋标本进行LMD，仅收集肿瘤细胞(OCT/LMD- t)或肿瘤和基质细胞(OCT/LMD- ts)，然后在37℃孵育。采用illustra triplePrep试剂盒提取蛋白质，胰蛋白酶消化，tmt标记，二维液相色谱-串联质谱(2D LC-MS/MS)处理。使用Proteome Discoverer v1.4对蛋白质进行鉴定和定量，并进行比较分析，以确定在不同处理方法中表达显著差异的蛋白质。结果:在所有样品中一致定量的4950种蛋白质中，有216种和171种蛋白质在FF/HOM与OCT/LMD-T和FF/HOM与OCT/LMD-TS之间的表达差异显著(调整p值1)，其中大多数蛋白质在FF/HOM样品中含量更高。用这216个和171个蛋白进行PCA和无监督分层聚类分析，可以分别将FF/HOM与OCT/LMD-T和OCT/LMD-TS样品区分开来。同样，PCA分析和无监督聚类分析使用402和60显著差异富集的GO项(调整p值(BH)引用格式:Lori A. Sturtz, Guisong Wang, Punit Shah, Richard Searfoss, Praveen-Kumar Raj-Kumar, Jeffrey A. Hooke, J. Leigh Fantacone-Campbell, Brenda Deyarmin, Mary Lou Cutler, Rangaprasad Sarangarajan, Niven R. Narain, Hai Hu, Michael A. Kiebish, Albert J. Kovatich, Craig D. Shriver。快闪冷冻与激光显微解剖oct包埋乳腺肿瘤标本LC-MS/MS定量蛋白差异分析[摘要]。参见:2020年圣安东尼奥乳腺癌虚拟研讨会论文集;2020年12月8-11日;费城(PA): AACR;癌症杂志，2021;81(4增刊):摘要nr PS18-38。
{"title":"Abstract PS18-38: Comparative analysis of differentially abundant proteins quantified by LC-MS/MS between flash frozen and laser microdissected OCT-embedded breast tumor samples","authors":"Lori A. Sturtz, Guisong Wang, Punit Shah, R. Searfoss, Praveen-Kumar Raj-Kumar, J. Hooke, J. Fantacone-Campbell, B. Deyarmin, M. Cutler, R. Sarangarajan, N. Narain, Hai Hu, M. Kiebish, A. Kovatich, C. Shriver","doi":"10.1158/1538-7445.SABCS20-PS18-38","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS18-38","url":null,"abstract":"Background: Proteomic studies are typically conducted using flash-frozen (FF) samples utilizing tandem mass spectrometry. However, FF samples are comprised of multiple cell types, making it difficult to ascertain the proteomic profiles of specific cells. Conversely, OCT-embedded (Optimal Cutting Temperature compound) specimens can undergo laser microdissection (LMD) to capture and study specific cell types separately from the cell mixture. In the current study, we compared proteomic data obtained from FF and OCT samples to determine if samples that are stored and processed differently produce comparable results. Methods: Proteins were extracted from FF and OCT-embedded invasive breast tumors from 5 female patients. FF samples were lysed via homogenization (FF/HOM) while OCT-embedded specimens underwent LMD to collect only tumor cells (OCT/LMD-T) or both tumor and stromal cells (OCT/LMD-TS) followed by incubation at 37°C. Proteins were extracted using the illustra triplePrep kit and then trypsin-digested, TMT-labeled, and processed by two-dimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS). Proteins were identified and quantified with Proteome Discoverer v1.4 and comparative analyses performed to identify proteins that were significantly differentially expressed amongst the different processing methods. Results: Among 4,950 proteins consistently quantified across all samples, 216 and 171 proteins were significantly differentially expressed (adjusted p-value 1) between FF/HOM vs. OCT/LMD-T and FF/HOM vs. OCT/LMD-TS, respectively, with most proteins being more highly abundant in the FF/HOM samples. PCA and unsupervised hierarchical clustering analysis with these 216 and 171 proteins were able to distinguish FF/HOM from OCT/LMD-T and OCT/LMD-TS samples, respectively. Likewise, PCA analysis and unsupervised clustering analysis using the 402 and 60 significantly differentially enriched GO terms (adjusted p-value (BH) Citation Format: Lori A. Sturtz, Guisong Wang, Punit Shah, Richard Searfoss, Praveen-Kumar Raj-Kumar, Jeffrey A. Hooke, J. Leigh Fantacone-Campbell, Brenda Deyarmin, Mary Lou Cutler, Rangaprasad Sarangarajan, Niven R. Narain, Hai Hu, Michael A. Kiebish, Albert J. Kovatich, Craig D. Shriver. Comparative analysis of differentially abundant proteins quantified by LC-MS/MS between flash frozen and laser microdissected OCT-embedded breast tumor samples [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS18-38.","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89231057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PS13-52
Yang Hongjian, Xingfei Yu, Chen Wang, Zheng Yabing, Huang Jiejie, X. Shao, L. Sheng, Juan Lin, Yuqin Ding, Haojun Xuan, Lijie Gong, W. Feng, Chengdong Qin, Dao-bao Chen, Yang Yu
{"title":"Abstract PS13-52: Preoperative systemic therapy versus upfront surgery in HER2-positive early breast cancer: A prospective nested case-control study in the real world","authors":"Yang Hongjian, Xingfei Yu, Chen Wang, Zheng Yabing, Huang Jiejie, X. Shao, L. Sheng, Juan Lin, Yuqin Ding, Haojun Xuan, Lijie Gong, W. Feng, Chengdong Qin, Dao-bao Chen, Yang Yu","doi":"10.1158/1538-7445.SABCS20-PS13-52","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PS13-52","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88659192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：